Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia

Phase 3CompletedNCT03024086

Daewoong Pharmaceutical Co. LTD.124 enrolled

Overview

The purpose of this study is to evaluate the Efficacy and Safety of DWJ1252 in treatment of Functional Dyspepsia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

124

Conditions

Functional Dyspepsia

Interventions

DWJ1252DRUG

DWJ1252 and Placebo of Gasmotin

GasmotinDRUG

Gasmotin and Placebo of DWJ1252

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male of female of at least 19 years old * Patient with functional dyspepsia met the ROME III criteria Exclusion Criteria: * Patients with previous gastrointestinal surgery * Patients with history of gastrointestinal bleeding, mechanical obstruction, perforation * Patients with history of gastrointestinal cancer

Locations (1)

Hanyang University Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

The change from baseline in GIS (Gastrointestinal Symptom Score)

Time frame: At 4 Weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.